Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    NCT01757535
Previous Study | Return to List | Next Study

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Celgene Corporation
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: November 21, 2012
Last updated: December 28, 2016
Last verified: December 2016
This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) following induction with or without consolidation chemotherapy. Subjects who have previously achieved CR/CRi with a hypomethylating agent will be excluded from the study.

Condition Intervention Phase
Leukemia, Myeloid, Acute
Drug: 300 mg Oral Azacitidine
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Resource links provided by NLM:

Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
    Number of participants who survive

Secondary Outcome Measures:
  • Relapse free survival (RFS) [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
    Number of participants who survive without relapsing

  • Complete Remission (CR)/Complete Remission with incomplete blood count recovery (CRi) [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    Time to relapse from Complete Remission (CR)/Complete Remission with incomplete blood count recovery (CRi)

  • Safety and Tolerability [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
    Number of participants with adverse events

  • Healthcare Resource Utilization [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    Effect of oral azacitidine compared with Placebo on healthcare utilization. Healthcare utilization data will be collected as described below: Information on each hospitalization will be collected utilizing a CRF designed specifically for this purpose. Information to be collected will include, but not be limited to, the reason for hospitalization (eg, disease relapse, AML-related illness, treatment-related AE), and days of hospitalization by treatment setting (inpatient, special care unit). Other disease- and treatment-related forms of healthcare utilization will be collected through routine study activities. These include diagnostic procedures and treatment interventions not requiring hospitalization such as those required for AML-related illness, or for treatment-related adverse events. Additionally, information on all concomitant medications and resource use associated with treatment administration for AML will be collected. Healthcare resource utilization information will be

  • Health-related quality-of-life (HRQoL) [ Time Frame: 60 months ] [ Designated as safety issue: No ]
    FACT-F Functional Assessment of Cancer Therapy-Fatigue, EuroQol-5D (EQ-5D) measure of health outcome and 3 additional exploratory questions

Estimated Enrollment: 460
Study Start Date: April 2013
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral Azacitidine
300mg Oral Azacitidine for the first 14 days of each 28 days treatment cycle
Drug: 300 mg Oral Azacitidine
Maintenance therapy
Placebo Comparator: Placebo
300 mg Placebo for the first 14 days of each 28 days treatment cycle
Drug: Placebo

Detailed Description:
This is an international, multicenter, placebo-controlled, phase3 study with a double-blind, randomized, parallel-group design with de novo AML (Acute Myeloid Leukemia) or AML secondary to prior diagnosis of Myelodysplasic Syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects ≥ 55 years of age
  2. Newly diagnosed, confirmed de novo AML or AML Secondary to prior myolodysplasic disease or CMML (Chronic myelomonocytic leukemia)
  3. First Complete remission (CR)/ Complete remission with incomplete blood count recovery (CRi) with induction therapy ± consolidation therapy within 4 months (± 7 days of achieving CR
  4. Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, 2, 3

Exclusion Criteria:

  1. AML with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) or molecular evidence of such translocations
  2. Prior bone marrow or stem cell transplantation
  3. Candidate for allogeneic bone marrow or stem cell transplant
  4. Have achieved CR/CRi following therapy with hypomethylating agents
  5. Diagnosis of malignant disease within the previous 12 months
  6. Proven Central Nervous System (CNS) leukemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01757535

Contact: Andrew Dorman, Study Manager +1 908-673-2076

  Show 220 Study Locations
Sponsors and Collaborators
Celgene Corporation
Study Director: Barry Skikne, MD Celgene Corporation
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Celgene Corporation Identifier: NCT01757535     History of Changes
Other Study ID Numbers: CC-486-AML-001  2012-003457-28 
Study First Received: November 21, 2012
Last Updated: December 28, 2016
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria : Bundesamt für Sicherheit im Gesundheitswesen
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Finland: Finnish Medicines Agency
Germany : BfArm : Bundesinstitut fur Arzneimittel und Medizinprodukte
Ireland : Irish Medicine Board
Israel: Ministry of Health
Italy: The Italian Medicines Agency
Lithuania: State Medicine Control Agency - Ministry of Health
Mexico: Ministry of Health
Poland : Office of Registration of Medicinal Products, Medical Devices and Biocidal Products
Portugal: National Pharmacy and Medicines Institute
South Korea: Korea Food and Drug Administration (KFDA)
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Russia: Ministry of Health of the Russian Federation
Turkey: Ministry of Health
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Taiwan : Food and Drug Administration

Keywords provided by Celgene Corporation:
Maintenance therapy
Acute Myeloid Leukemia
oral Azacitidine
best supportive care
complete remission

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors processed this record on January 18, 2017